CN105504009A - 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 - Google Patents
一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 Download PDFInfo
- Publication number
- CN105504009A CN105504009A CN201410498354.3A CN201410498354A CN105504009A CN 105504009 A CN105504009 A CN 105504009A CN 201410498354 A CN201410498354 A CN 201410498354A CN 105504009 A CN105504009 A CN 105504009A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- dpp
- gly
- pro
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 20
- 241000282994 Cervidae Species 0.000 title claims abstract description 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims abstract 6
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title claims abstract 6
- 230000002401 inhibitory effect Effects 0.000 title abstract description 4
- 210000002435 tendon Anatomy 0.000 title abstract 2
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 208000008589 Obesity Diseases 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 235000020824 obesity Nutrition 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 208000019622 heart disease Diseases 0.000 claims abstract description 4
- 229930182817 methionine Natural products 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 6
- 150000002611 lead compounds Chemical class 0.000 abstract description 3
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 30
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 30
- 239000000523 sample Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 238000013016 damping Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 5
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 4
- 108010077515 glycylproline Proteins 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 238000010847 SEQUEST Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种源于鹿筋的具有DPP-IV抑制活性的多肽化合物GPM*GPP#GVK，其氨基酸序列为Gly-Pro-Xaa-Gly-Pro-Hyp-Gly-Val-Lys，其中Xaa为蛋氨酸(Met)的氧化物。多肽GPM*GPP#GVK具有DPP-IV抑制活性及降血糖活性，作为糖尿病、心脏病、心血管病、肥胖症、肾病、免疫紊乱等疾病的保健品和药物先导化合物具有良好的应用前景。
Description
技术领域
本发明涉及多肽GPM*GPP#GVK在制备抑制二肽基肽酶—IV(DPP-IV)及降血糖中的应用。
背景技术
二肽基肽酶—IV(dipeptidylpeptidase-IV，DPP-IV)(EC3.4.14.5)是一种丝氨酸蛋白酶，广泛分布于人体内。DPP-IV通过对多肽的剪切使其失活，从而达到调节生理功能的作用。DPP-IV优先水解N-末端第二位上具有脯氨酸(Pro)或丙氨酸(Ala)的蛋白质。其作用底物包括：胰高血糖素样肽-1(GLP217-36)、抑胃肽(GIP1-42)、神经肽(NPY)、YY肽(PYY)以及胰多肽家族(PP-family)等。这些物质的共同特点就是N-末端第二位的氨基酸残基或者是脯氨酸或者是丙氨酸残基。DPP-IV通过作用于以上多肽底物而在糖尿病、葡萄糖耐量、肥胖、食欲调节、高血脂症、骨质疏松、神经肽新陈代谢和T-细胞激活等相关疾病中起着重要的作用。因此，体内给予DPP-IV抑制剂可预防相关底物肽的N-末端降解，从而保障人体机能正常运行。
DPP-IV将完整的GLP-1和GIP反应切断N-末端2个氨基酸残基后，使其失活从而影响GLP-1和GIP相关的血糖调节等生理反应。体内给予DPP-IV抑制剂可预防GLP-1和GIP的N-末端降解，使胰岛素分泌物增加从而改善葡萄糖耐量。鉴于DPP-IV抑制剂与血糖代谢的密切关系，DPP-IV抑制剂已成为新型2型糖尿病药物的研究热点。
发明内容
本发明的目的是提供多肽GPM*GPP#GVK在抑制DPP-IV活性和降血糖中的应用；多肽GPM*GPP#GVK具有DPP-IV抑制活性及降血糖活性，作为糖尿病、心脏病、心血管病、肥胖症、肾病、免疫紊乱等疾病的保健品和药物先导化合物具有良好的应用前景。
为实现上述目的，本发明以所述多肽GPM*GPP#GVK为抑制DPP-IV活性和降血糖的有效成份。
其具有序列表SEQIDNO：1中氨基酸序列；多肽GPM*GPP#GVK为DPP-IV抑制剂及降血糖药物的活性成份，其中可添加药物学上可接受的载体或辅料。
具有抑制DPP-IV活性和降血糖活性的多肽化合物GPM*GPP#GVK的氨基酸序列为Gly-Pro-Xaa-Gly-Pro-Hyp-Gly-Val-Lys，其中Xaa为蛋氨酸(Met)的氧化物。单链线性结构，分子量为871Da，白色粉末状，易溶于水，对DPP-IV活性具有很强的抑制作用，IC50为197.79μM。
多肽GPM*GPP#GVK具备DPP-IV抑制剂所要求的特征：DPP-IV优先水解N-末端第二位上具有脯氨酸(Pro)或丙氨酸(Ala)的蛋白质或肽，GPM*GPP#GVK的N-末端第二位上是脯氨酸(Pro)。
本发明与现有技术相比，具有如下有益效果：
本发明首次从鹿筋中获得并确定了活性化合物的结构，化合物具有较好的抑制DPP-IV的活性，因此作为糖尿病、心脏病、心血管病、肥胖症、肾病、免疫紊乱等疾病的保健品和药物先导化合物具有良好的应用前景。
具体实施方式
实施例1多肽GPM*GPP#GVK的制备
100g新鲜的马鹿鹿筋，用质量浓度10％NaOH于50℃煮30分钟进行脱脂处理后，纯水清洗干净，剪为2～3平方厘米的碎片。鹿筋碎片按照1:80(原料：缓冲液质量比)加入0.01M醋酸缓冲液，再按1:100(酶：原料)质量比加入胃蛋白酶，于40℃搅拌反应2小时。将上述反应液的pH用1MNaOH调至7，加入复合酶(糜胰蛋白酶，中性蛋白酶，质量混合比例1:1)进行酶解，加酶量为反应物质量的0.1％，于40℃搅拌反应3小时，反应结束后90℃灭活20min。将上述反应液5000rpm离心5min，收集上清，上述酶解产物经制备色谱分离，色谱柱为C18(20X250mm，10μm),所用的流动相A为质量浓度0.1％甲酸/水溶液，流动相B为质量浓度0.1％的甲酸/乙腈溶液，流速为2mL/min，洗脱过程如下：5％B—35％B(V/V)—80％B(V/V)。将在280nm下所检测到的色谱峰分别收集得到不同组分冷冻干燥，为乳白色粉末状样品。
所得样品分别经反相液相色谱-串联质谱系统(RPLC-MS/MS)分析：将冷冻干燥后的酶解样品用体积浓度0.1％甲酸溶液配制为0.4μg/μL，进样20μL进行LTQ线性离子阱质谱(配置纳升级电喷雾源)分析。利用Xcalibur软件(Thermo)进行系统控制和数据收集。实验得到的质谱数据结果分别在honeybee,BrassicacampestrisL.蛋白质数据库(http://www.uniprot.org/)中进行检索，技术重复3次，数据库检索软件为SEQUEST。获得序列为Gly-Pro-Xaa-Gly-Pro-Hyp-Gly-Val-Lys，其中Xaa为蛋氨酸(Met)的氧化物。
实施例2多肽GPM*GPP#GVK的DPP-IV抑制活性检测
(1)原理
采用以甘氨酰脯氨酸对硝基苯胺(Gly-Pro-PNA)为底物的发色底物法筛选DPP-IV抑制剂，该方法的检测原理为在碱性条件下DPP-IV催化底物Gly-Pro-p-nitroanilide水解,生成黄色的对硝基苯胺,后者在波长405nm处有特征性吸收峰，通过酶标仪在405nm处测得的吸光度大小反映酶活性高低。
(2)方法
样品：将样品溶解于100mM的Tris-HCl缓冲液(pH＝8.0)，配成40mg/mL储备液，再将储备液稀释成不同的浓度，作为样品溶液。
底物：Gly-pro-p-nitroanilide溶液，用100mM的Tris-HCl缓冲液(pH＝8.0)将Gly-pro-p-nitroanilide配置成1.59mM的Gly-pro-p-nitroanilide溶液。
酶：DPP-IV溶液，用100mM的Tris-HCl缓冲液(pH＝8.0)配置成0.01U/mL的DPP-IV溶液。
终止溶液：1M的醋酸—醋酸钠缓冲液(pH＝4.0)。
实验在96孔板中进行，利用酶标仪在405nm检测吸光度。首先将酶、缓冲液及药物在37℃温度下分别水浴30min,然后将样品(或缓冲液)、底物依次加入96孔板内37℃孵育10分钟，再加入DPP-IV酶溶液，混匀后于37℃温育60分钟，加入100μL1M的醋酸-醋酸钠缓冲液(pH4.0)使反应终止。用酶标仪测定405nm吸光度(OD)。反应总体积为100μl。实验分为4组,每组设3个复孔。各组分别为：
样品组(S组)：样品+酶+底物。
样品空白组(SB组)：样品+底物。
阴性对照组(C组)：酶+底物。
空白组(B组)：底物。
具体各组加样品见表1。
表1DPP-VI抑制活性实验分组及加样量
注：(1)表中数字的单位均为μl。
(2)反应总体积为100μl，各组按照表中所列加入反应物后用缓冲液将最终体积补至100μl。
(3)抑制率的计算
(4)检测结果
分别用12.5μg/ml,25μg/ml，50μg/ml，100μg/ml，250μg/ml，500μg/ml的多肽浓度，按上述方法进行DPP-IV抑制活性检测。结果如下表：
经IC50计算器计算该序列的IC50为197.79μg/mL，即227.08μM。
Claims (4)
1.一种源于鹿筋的具有DPP-IV抑制活性的多肽，其特征在于：所述多肽为GPM*GPP#GVK，具有序列表SEQIDNO：1中氨基酸序列；该多肽的氨基酸序列具体为，Gly-Pro-Xaa-Gly-Pro-Hyp-Gly-Val-Lys,其中Xaa为蛋氨酸(Met)的氧化物。
2.一种权利要求1所述多肽在制备DPP-IV抑制剂或降血糖药物中的应用。
3.按照权利要求2所述的应用，其特征在于：所述DPP-IV抑制剂及降血糖药物是以多肽GPM*GPP#GVK为活性成份，其中可添加药物学上可接受的载体或辅料。
4.按照权利要求2所述的应用，其特征在于：所述多肽在制备预防和/或治疗糖尿病、心脏病、心血管病、肥胖症、肾病、免疫紊乱中的一种或二种以上疾病药物和/或保健品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410498354.3A CN105504009B (zh) | 2014-09-24 | 2014-09-24 | 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410498354.3A CN105504009B (zh) | 2014-09-24 | 2014-09-24 | 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105504009A true CN105504009A (zh) | 2016-04-20 |
| CN105504009B CN105504009B (zh) | 2018-10-09 |
Family
ID=55712364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410498354.3A Expired - Fee Related CN105504009B (zh) | 2014-09-24 | 2014-09-24 | 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105504009B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110776557A (zh) * | 2018-07-27 | 2020-02-11 | 中国科学院大连化学物理研究所 | 多肽及其应用和dpp-ⅳ抑制剂或降血糖药物或保健品 |
| CN111812333A (zh) * | 2020-06-29 | 2020-10-23 | 吉林省东北亚生物科技有限公司 | 对比鹿筋天然肽和酶解肽抗类风湿性关节炎活性的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475884A (zh) * | 2010-11-29 | 2012-05-30 | 中国科学院大连化学物理研究所 | 四个多肽在制备ace抑制剂及降血压药物中的应用 |
| CN102834108A (zh) * | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| JP2013040111A (ja) * | 2011-08-11 | 2013-02-28 | Okayama Prefecture | ジペプチジルペプチダーゼ−ｉｖ阻害剤及びその製造方法 |
| CN103044391A (zh) * | 2011-10-13 | 2013-04-17 | 中国科学院广州生物医药与健康研究院 | 一种高效的dpp-iv抑制剂 |
| CN103483418A (zh) * | 2013-09-12 | 2014-01-01 | 陈尚武 | 一种dpp-ⅳ抑制多肽及其应用 |
-
2014
- 2014-09-24 CN CN201410498354.3A patent/CN105504009B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102834108A (zh) * | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| CN102475884A (zh) * | 2010-11-29 | 2012-05-30 | 中国科学院大连化学物理研究所 | 四个多肽在制备ace抑制剂及降血压药物中的应用 |
| JP2013040111A (ja) * | 2011-08-11 | 2013-02-28 | Okayama Prefecture | ジペプチジルペプチダーゼ−ｉｖ阻害剤及びその製造方法 |
| CN103044391A (zh) * | 2011-10-13 | 2013-04-17 | 中国科学院广州生物医药与健康研究院 | 一种高效的dpp-iv抑制剂 |
| CN103483418A (zh) * | 2013-09-12 | 2014-01-01 | 陈尚武 | 一种dpp-ⅳ抑制多肽及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| ISABELLE M.E. LACROIX: "Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates", 《INTERNATIONAL DAIRY JOURNAL》 * |
| 李祎亮: "二肽基肽酶IV抑制剂的研究进展", 《中国新药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110776557A (zh) * | 2018-07-27 | 2020-02-11 | 中国科学院大连化学物理研究所 | 多肽及其应用和dpp-ⅳ抑制剂或降血糖药物或保健品 |
| CN110776557B (zh) * | 2018-07-27 | 2023-02-28 | 中国科学院大连化学物理研究所 | 多肽及其应用和dpp-ⅳ抑制剂或降血糖药物或保健品 |
| CN111812333A (zh) * | 2020-06-29 | 2020-10-23 | 吉林省东北亚生物科技有限公司 | 对比鹿筋天然肽和酶解肽抗类风湿性关节炎活性的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105504009B (zh) | 2018-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fu et al. | Exploration of collagen recovered from animal by-products as a precursor of bioactive peptides: Successes and challenges | |
| Wang et al. | Dipeptidyl peptidase IV inhibitory peptides derived from oat (Avena sativa L.), buckwheat (Fagopyrum esculentum), and highland barley (Hordeum vulgare trifurcatum (L.) Trofim) proteins | |
| Zhang et al. | Dipeptidyl peptidase IV-inhibitory peptides derived from silver carp (Hypophthalmichthys molitrix Val.) proteins | |
| CN105273081A (zh) | 一种二肽基肽酶iv抑制肽及其制备和应用 | |
| Gong et al. | Prospects of cereal protein-derived bioactive peptides: Sources, bioactivities diversity, and production | |
| Lacroix et al. | Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins | |
| EP2874642B1 (en) | Anti-inflammatory proteins and peptides and methods of preparation and use thereof | |
| CA2575756A1 (en) | Combination therapy using transferrin fusion proteins comprising glp-1 | |
| EP1626981A2 (en) | Dipeptidyl-peptidase protected proteins | |
| de Matos et al. | Production of black cricket protein hydrolysates with α-amylase, α-glucosidase and angiotensin I-converting enzyme inhibitory activities using a mixture of proteases | |
| RU2014104302A (ru) | Слитые белки, высвобождающие релаксин, и их применение | |
| Zhang et al. | Rapid screening of novel dipeptidyl peptidase-4 inhibitory peptides from pea (Pisum sativum L.) protein using peptidomics and molecular docking | |
| Shen et al. | Expression of recombinant AccMRJP1 protein from royal jelly of Chinese honeybee in Pichia pastoris and its proliferation activity in an insect cell line | |
| CN105504009A (zh) | 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 | |
| Retzl et al. | Discovery of a beetroot protease inhibitor to identify and classify plant-derived cystine knot peptides | |
| CN106554387B (zh) | 具有ace和dpp-iv双重抑制活性的九肽及其应用 | |
| CN105440102A (zh) | 一种源于鹿皮的具有dpp-iv抑制活性的多肽及其应用 | |
| CN105504010A (zh) | 一种具有dpp-iv抑制活性的多肽及其应用 | |
| Fadimu et al. | Enhancing the biological activities of food protein-derived peptides using non-thermal technologies: a review | |
| CN106554388B (zh) | 具有ace和dpp-iv抑制活性的多肽及其应用 | |
| CN108929370B (zh) | 三种具有ace抑制活性的鸡蛋源活性肽 | |
| CN105504011A (zh) | 一种具有dpp-iv抑制活性的多肽及其在降血糖药物中的应用 | |
| CN105504008A (zh) | 一种具有dpp-iv抑制活性的鹿肽及其应用 | |
| CN111000984A (zh) | 一组蛇神经生长因子及蛇神经生长因子前体在治疗老年痴呆上的应用 | |
| CN101215594B (zh) | 连续酶膜反应制备马氏珠母贝降血压肽的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181009 |